Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00418015 · ClinicalTrials.gov registry record

Mu-Opioid Receptor Genetic Polymorphism and Intrathecal Analgesia

A clinical trial of Labor Pain and Post-cesarean Delivery, sponsored by Northwestern University.

Completed
Registry status
293
Enrollment target
1
Study location

NCT00418015 is a study of Labor Pain and Post-cesarean Delivery that has completed, run by Northwestern University. The registered enrollment target is 293 participants, above the 183-participant average among 14 other Labor Pain trials with a reported enrollment target (60% higher). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00418015, a study of Labor Pain and Post-cesarean Delivery, has completed, sponsored by Northwestern University.

COMPLETED
Registry status
293 participants
Enrollment target
1
Study location

Study Summary

Pharmacogenetics has allowed clinicians to identify associations between an individual's genetic profile and his/her response to drugs. The A118G (c.188A\>G)is a single nucleotide polymorphism (SNP) of the mu-opioid receptor (OPRM1). The mutated protein, N40D, appears to increase the binding affinity and potency of beta-endorphin approximately 3-fold. Individuals carrying the variant receptor gene (A118G) may show differences in some of the functions mediated by beta-endorphin action at the altered OPRM1. Combined spinal-epidural (CSE) analgesia is a commonly utilized technique for labor analgesia. Analgesia is initiated with the intrathecal administration of a lipid-soluble opioid (e.g. fentanyl), sometimes combined with a local anesthetic. The mean (± SD) duration of analgesia after intrathecal fentanyl 25 microgram was 89 ± 43 min. The ED50 of intrathecal fentanyl for labor analgesia varies between 14 microgram to 18.2 microgram. The wide variability in the duration of analgesia, as was well the differences in ED50 may result from differences known to affect labor pain (e.g., ethnicity, parity, stage of labor). Another possible explanation for the differences in opioid requirements and duration, as well as incidence of side effects such as itching and nausea/vomiting, is that opioid responsiveness is determined by genetic variability of the µ-opioid receptor. The ED50 for intrathecal fentanyl labor analgesia was significantly lower for parturients carrying the A118G variant of the mu-opioid receptor, compared to parturients with the A118 wild type receptor. The purpose of this study is to determine whether polymorphism at nucleotide 118 of OPRM1 influences the duration of intrathecal opioid (fentanyl) labor analgesia, and intrathecal opioid (morphine) postoperative analgesia.

Interventions

  • PROCEDURE Blood Draw

Study Locations (1)

Illinois

  • Northwestern University - Chicago

Trial Details

FieldValue
Enrollment Target 293 participants
Start Date 2005-10
Est. Completion 2007-06

Sponsor

Northwestern University

1,209 total trials

What the Registry Record Tells You About NCT00418015

The ClinicalTrials.gov registry entry for NCT00418015 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 293 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 183-participant average among 14 other Labor Pain trials with a reported enrollment target (60% higher). The listed sponsor is Northwestern University, which has 1,209 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Labor Pain appearing as the primary indexed condition, and to 1 intervention - of which Blood Draw is the first listed.

NCT00418015 reports 1 study location spanning 1 distinct geographic area - top geographies include Illinois.

Frequently Asked Questions

What is clinical trial NCT00418015 about?

NCT00418015 is a clinical study titled "Mu-Opioid Receptor Genetic Polymorphism and Intrathecal Analgesia". Pharmacogenetics has allowed clinicians to identify associations between an individual's genetic profile and his/her response to drugs. The A118G (c.188A\>G)is a single nucleotide polymorphism (SNP) of the mu-opioid receptor (OPRM1). The mutated protein, N40D, appears to increase the binding affinit...

What is the current status of trial NCT00418015?

This trial is currently completed. The enrollment target is 293 participants. The study started on 2005-10. Estimated completion is 2007-06.

What conditions does trial NCT00418015 study?

This clinical trial studies the following conditions: Labor Pain, Post-cesarean Delivery.

What interventions are being tested in trial NCT00418015?

The interventions under investigation include: Blood Draw (PROCEDURE).

Who is sponsoring clinical trial NCT00418015?

This trial is sponsored by Northwestern University, which has 1,209 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00418015 being conducted?

This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Labor Pain

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.